CD34 and acute myeloid leukemia: As shown in Fig. 2A-a&b, most primary CD34+ AML cells were very sensitive to both PepE and DMAPE treatment and show strong response starting at 6 μM (average 24.01% cells viable after PepE treatment and 28.85% cells after DMAPE treatment).